Premium
Treatment of intrabony periodontal defects using rh FGF ‐2 in combination with deproteinized bovine bone mineral or rh FGF ‐2 alone: A 6‐month randomized controlled trial
Author(s) -
Saito Atsushi,
Bizenjima Takahiro,
Takeuchi Takahiro,
Suzuki Eiichi,
Sato Masahiro,
Yoshikawa Kouki,
Kitamura Yurie,
Matsugami Daisuke,
Aoki Hideto,
Kita Daichi,
Imamura Kentaro,
Irokawa Daisuke,
Seshima Fumi,
Tomita Sachiyo
Publication year - 2019
Publication title -
journal of clinical periodontology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.456
H-Index - 151
eISSN - 1600-051X
pISSN - 0303-6979
DOI - 10.1111/jcpe.13086
Subject(s) - medicine , dentistry , periodontitis , randomized controlled trial , bone mineral , prom , urology , osteoporosis , obstetrics
Aim To evaluate the use of recombinant human fibroblast growth factor (rh FGF )‐2 in combination with deproteinized bovine bone mineral ( DBBM ) compared with rh FGF ‐2 alone, in the treatment of intrabony periodontal defects. Materials and Methods Patients with periodontitis who had received initial periodontal therapy and had intrabony defects of ≥ 3 mm in depth were enrolled. Sites were randomly assigned to receive a commercial formulation of 0.3% rh FGF ‐2 + DBBM (test) or rh FGF ‐2 alone (control). Clinical parameters and a patient‐reported outcome measure ( PROM ) were evaluated at baseline and at 3 and 6 months postoperatively. Results Twenty‐two sites in each group were evaluated. A significant improvement in clinical attachment level ( CAL ) from baseline was observed in both groups at 6 months postoperatively. CAL gain was 3.16 ± 1.45 mm in the test group and 2.77 ± 1.15 mm in the control group, showing no significant difference between groups. Radiographic bone fill was significantly greater in the test group (47.2%) than in the control group (29.3%). No significant difference in PROM between groups was observed. Conclusions At 6 months, no significant difference in CAL gain or PROM between the two treatments was observed, although combination therapy yielded an enhanced radiographic outcome.